Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma
暂无分享,去创建一个
D. Cunningham | M. Dreyling | B. Childs | F. Morschhauser | U. Vitolo | S. Assouline | K. Bouabdallah | E. Neste | S. Mappa | J. Grunert | M. Giurescu